Early attempts to describe the natural history of cervical cancer were based on the assumption that the disease has a slow and regular progression from normal epithelium to invasive carcinoma over a period of several years.' The correlation between age at diagnosis and clinical stage was one of the strongest indications in favour of this assumption. These views were largely accepted and today mass screening programmes are based on this basic model of the natural history of cervical cancer. Another interpretation of the epidemiological observations was given by Ashley2 who proposed that there are two types of cervical cancer, one slow growing with relatively good prognosis and occurring in younger women, the other fast growing, less susceptible to cure, and occurring in older women. The purpose of this paper is to make inferences on the natural history of cervical cancer on the basis of the clinical course of the disease, using observations of incidence, of delay in the start of treatment, and of long-term survival.
Early attempts to describe the natural history of cervical cancer were based on the assumption that the disease has a slow and regular progression from normal epithelium to invasive carcinoma over a period of several years.' The correlation between age at diagnosis and clinical stage was one of the strongest indications in favour of this assumption. These views were largely accepted and today mass screening programmes are based on this basic model of the natural history of cervical cancer. Another interpretation of the epidemiological observations was given by Ashley2 who proposed that there are two types of cervical cancer, one slow growing with relatively good prognosis and occurring in younger women, the other fast growing, less susceptible to cure, and occurring in older women. The purpose of this paper is to make inferences on the natural history of cervical cancer on the basis of the clinical course of the disease, using observations of incidence, of delay in the start of treatment, and of long-term survival. The first course of treatment was recorded by both registries and patients were classified into the following groups: (i) surgery (ii) radiotherapy (iii) combined surgery and radiotherapy and (iv) other or no known therapy. The patients were followed up until the end of 1975.
Duration of symptoms was not included on the magnetic tapes of the registry material so a sample of about 100 records of patients with cervical cancer was drawn from the original files of the cancer registries in both countries.
Results
The The overall five-year survival rates were 70% in Finland and 54% in South Wales (Table 2) . However, the simple observed five-year survival rates showed very little difference between the two countries when the extent of the disease, or the clinical staging, was taken into account. Relative survival curves for carcinoma-in-situ, localised, and non-localised carcinomas to 10 years after registration showed a small advantage to Finland for localised carcinomas and for the first two years for non-localised carcinomas only (Figure) . The mean age at diagnosis for patients with localised carcinoma was eight or nine years greater than for those with a carcinoma-in-situ and the mean age at diagnosis for those with non-localised carcinoma was five or six years greater again (Table  3) . In Finland the mean ages were one to two years higher than in South Wales for all three stages.
The distribution of treatments in the two countries was similar (Table 4) . Radiotherapy alone was the most common treatment and it was given slightly more frequently in Finland than in South Wales.
The delay from the time of first symptoms to the time of treatment ranged from three to 10 months in different subgroups of patients by country and stage of disease (Table 5) 
Discussion
The clinical stage at diagnosis depends partly on the malignancy of the lesion with which is associated the speed of growth, and partly on the delay between the first symptoms and confirmation of the diagnosis. The former is a characteristic of the tumour and/or the host whereas the latter is a characteristic of the host and/or the health care system. The former refers to the immunological and the latter to the behavioural characteristics of the host.
The delay can be affected by an individual or by the health care organisation via the timing of the diagnosis, which in turn affects the results of treatment. In contrast, the speed of'tumnour growth is a biological characteristic which cannot be influenced by an individual or by a health care organisation. Below we discuss details of the survival pattern by stage and by country which are due to delay from first symptoms to diagnosis (lead time) and to the differences in the biological host characteristics and malignancy of the tumour.
In both countries patients with carcinoma-in-situ lesions experience roughly the normal life expectancy. For clinical carcinomas of the cervix the average loss in the expected length of life after diagnosis of the disease is about 25% in Finland and about 55% in Wales. Patients with non-localised (stage II, III, and IV) cancer may expect to lose two-thirds of their remaining years in both countries. The loss of life expectancy for patients-with localised cancer at diagnosis was one-third in South Wales and one-sixth in Finland. Therefore, the -difference in overall survival between the countries was due to both the poor survival among Welsh patients with localised disease at diagnosis and the high frequency of non-localised cases compared with Finnish women.
The number of in-situ carcinomas depends on the extent of screening in the population and on activity within the health care system. Screening was practised more in Finland than in South Wales.9 10
The more unfavourable distribution by stage of clinical carcinomas in Wales can be partly ascribed to the differences in the population distribution by age'9; because the mean age of the total female population in Wales is higher than in Finland and because stage of disease and age are positively correlated.
The possibility remains that some of the differences are due to differences in The first of these observationsfits the basic model of the natural history of cervical cancer.1 However, the second observation favours the hypothesis proposed by Ashley,2 according to which there are at least two forms of cervical cancer distinguished by age of appearance and speed of growth. There is no evidence that delay by Welsh patients with localised disease resulted in progress of localised to non-localised cancer, because tumours with long duration of symptoms were still localised at diagnosis. This further supports the hypothesis that localised tumours are slow growing ones. Finnish women may react more rapidly than the Welsh to mild and non-specific symptoms of slow growing tumours. In summary, population differences in age structure, delay between first symptoms and diagnosis, and differences in the biological characteristics of the disease are likely to account for the difference in survival between Finland and Wales. The natural history of cervical cancer may be more complicated than that of several other epithelial tumours, for which the speed of growth and the age of the patient are seldom correlated.
